Side-by-side · Research reference
Follistatin-344vsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED4/58 cited
BFDA-ApprovedFlagship15/53 cited
Follistatin-344
Myostatin/Activin Antagonist · Research Use
15–25%FST/MSTN ratio ↑
344 AACirculating isoform
ResearchPhase status
Research · No approved protocol
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Follistatin-344
Semaglutide
Primary target
Myostatin (MSTN/GDF-8) and Activin A
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — indirect antagonist, preserves endogenous regulation
Glucose-dependent insulin release preserves physiological feedback
Origin
Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
Not documented in available trials (endogenous protein)
—
02Dosage Protocols
Parameter
Follistatin-344
Semaglutide
Clinical protocol
None — no approved dosing regimen
Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.
—
Research context
Endogenous modulation via exercise + nutrition
Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).
—
Evidence basis
Human observational / biomarker studies
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Half-life
Not established
Circulating isoform; lacks tissue-binding domain of FST-315.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Frequency
—
Once weekly, same day each week
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
03Metabolic / Fat Loss Evidence
Parameter
Follistatin-344
Semaglutide
Primary target
Muscle mass preservation, not direct lipolysis
—
Indirect fat effect
Increased lean mass → elevated resting metabolic rate
Not primary mechanism. Muscle-sparing during deficit.
—
Clinical evidence
Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026
Suggests follistatin not primary driver of fat loss in weight-reduction interventions.
—
GLP-1RA studies
Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes
—
04Side Effects & Safety
Parameter
Follistatin-344
Semaglutide
Clinical safety data
None — no human exogenous administration trials in literature
—
Theoretical risks
Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance
Based on myostatin-null animal models and clinical myostatin inhibitor trials.
—
Endogenous elevation (exercise)
No adverse effects reported in 12-week resistance + EAA trials
—
Cancer risk (theoretical)
Myostatin inhibition may promote tumor growth in malignancy (preclinical data)
—
Regulatory status
Not approved for human use — research peptide only
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Follistatin-344
- ·Active malignancy
- ·No approved protocol — research use only
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Follistatin-344
- ·Insulin resistance / Type 2 diabetes (monitor glucose)
- ·Pregnancy / lactation (unknown safety profile)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Follistatin-344
Semaglutide
1. Regulatory status
Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Endogenous modulation
Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Measurement context
Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Research consideration
Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
—
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Follistatin-344
+ BPC-157
Multi-pathwayFollistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.
- Follistatin-344
- No approved protocol — endogenous modulation via resistance exercise + EAA
- BPC-157
- 250–500 mcg SQ · twice daily · near injury site or systemic
- Duration
- 4–8 weeks
- Primary benefit
- Muscle hypertrophy + accelerated soft tissue repair
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.
- Follistatin-344
- Endogenous upregulation (resistance training + protein)
- TB-500
- 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
- Frequency
- Twice weekly TB-500, daily training stimulus for FST
- Primary benefit
- Enhanced recovery, reduced inflammation, muscle growth support
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)